Rectal Cancer Clinical Trials in Beijing, Beijing Municipality
26 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 26 trials
Recruiting
Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer
Locally Advanced Rectal Cancer (LARC)
Beijing Friendship Hospital60 enrolled1 locationNCT07393048
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting
Phase 4
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
Rectal Cancer
Beijing Chao Yang Hospital966 enrolled1 locationNCT07209787
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
Phase 2
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Phase 1Phase 2
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Advanced Solid Tumors CancerPDACCRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc.126 enrolled4 locationsNCT07259590
Recruiting
Phase 3
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc.165 enrolled1 locationNCT06008119
Recruiting
Phase 1Phase 2
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.72 enrolled27 locationsNCT07044908
Recruiting
Phase 2
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
Advanced Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.60 enrolled2 locationsNCT06885385
Recruiting
Not Applicable
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1,384 enrolled8 locationsNCT06146946
Recruiting
Phase 1
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
Colorectal Cancer (CRC)
Beijing Immunochina Medical Science & Technology Co., Ltd.9 enrolled1 locationNCT06718738
Recruiting
Not Applicable
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
Colon CancerRectal CancerChemotherapy Effect+2 more
Peking Union Medical College Hospital200 enrolled1 locationNCT05424692
Recruiting
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
Phase 2
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences68 enrolled1 locationNCT06543836
Recruiting
Phase 2
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Metastatic Colorectal CancerRAS MutationMSS
Beijing Hospital60 enrolled1 locationNCT06321081
Recruiting
Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer （NORESTO Study）
Rectal Cancer
Peking Union Medical College Hospital235 enrolled1 locationNCT06194708
Recruiting
Phase 2
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
Rectal CancerMSS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences92 enrolled1 locationNCT05815303
Recruiting
Phase 2
Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
dMMR Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05815290
Recruiting
Not Applicable
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Neoadjuvant TherapyMetastasisRectal Cancer+1 more
Beijing Chao Yang Hospital260 enrolled1 locationNCT04743102